KCNK2
Potassium channel subfamily K member 2
As of the edition of 20 October 2026, KCNK2 (potassium channel subfamily K member 2, UniProt O95069) has 5 drugs tested at it and 4 companies on the list, 0 on route A and 2 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- O95069
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- In more than one place
- Solved structures
- 1
- Disease areas
- Nervous system; Heart and blood vessels; Mental health; Cancer; Lungs and airways; Urinary and reproductive; Digestive system; Pregnancy and women's health
- Registered trials of its drugs
- 385
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 5 |
| Total | 5 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Sevoflurane | Marketed | Phase 4 | none listed |
| Desflurane | Marketed | Phase 4 | none listed |
| Isoflurane | Marketed | Phase 4 | none listed |
| Enflurane | Marketed | No phase stated | none listed |
| Halothane | Marketed | No phase stated | none listed |
5 of 5 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route B | 2 |
| Undetermined | 2 |
| Total on the list | 4 |
| Company | Route |
|---|---|
| AbbVie | Route B |
| Baxter Healthcare | Route B |
The other 2 companies at KCNK2
In the product4 companies in all; 2 are not named here, and no score is.
See the 4 companies at KCNK2, ranked, with the facts behind eachRequest access. Nothing is shown until you do.